title: An updated review on cancer risk associated with incretin mimetics and enhancers.
abstract: Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1 receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) inhibitors, are widely used by clinicians for glucose lowering in patients with type 2 diabetes mellitus. These agents have benefits of a lower risk of hypoglycemia, being neutral for body weight for DPP-4 inhibitors and having a potential for weight reduction with GLP-1R agonists. They may also have a neutral or beneficial cardiovascular effect. Despite these benefits, an increased risk of cancer (especially pancreatic cancer and thyroid cancer) associated with incretin-based therapies has been reported. In this article, we reviewed related literature of experimental animal and observational human studies, clinical trials, and meta-analyses published until December 15, 2014. Current studies suggested a probable role of GLP-1R activation on the development of pancreatic cancer and thyroid cancer in rodents, but such an effect in humans is not remarkable due to the lower or lack of expression of GLP-1R on human pancreatic ductal cells and thyroid tissues. Findings in human studies are controversial and inconclusive. In the analyses of the US Food and Drug Administration adverse events reporting system, a significantly higher risk of pancreatic cancer was observed for GLP-1R agonists and DPP-4 inhibitors, but a significantly higher risk of thyroid cancer was only observed for GLP-1R agonists. Such a higher risk of pancreatic cancer or thyroid cancer could not be similarly demonstrated in other human observational studies or analyses of data from clinical trials. With regards to cancers other than pancreatic cancer and thyroid cancer, available studies supported a neutral association in humans. Some preliminary studies even suggested a potentially beneficial effect on the development of other cancers with the use of incretins. Based on current evidence, continuous monitoring of the cancer issues related to incretin-based therapies is required, even though the benefits may outweigh the potential cancer risk in the general patients with type 2 diabetes mellitus.
authors: a Department of Internal Medicine , National Taiwan University Hospital , Taipei , Taiwan.
authors: Chin-Hsiao
authors: CH
authors: Tseng
authors: Kuo-Yang
authors: KY
authors: Lee
authors: Farn-Hsuan
authors: FH
authors: Tseng
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D054795:Incretins / Q000009:adverse effects* / Q000627:therapeutic use; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D010190:Pancreatic Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D012307:Risk Factors; D013964:Thyroid Neoplasms / Q000139:chemically induced / Q000453:epidemiology
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins
keywords: diabetes mellitus; dipeptidyl-peptidase 4 inhibitor; glucagon-like peptide-1; incretin; pancreatic cancer; thyroid cancer